Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia.

AVP-786 comprises deuterium-modified dextromethorphan -- an NMDA receptor antagonist, σ-1 receptor agonist and inhibitor of serotonin and norepinephrine transporters -- plus ultra-low-dose quinidine, a CYP2D6 inhibitor...